Opportunity Information: Apply for PA 16 296
Apply for PA 16 296
- The HHS-NIH11 in the health sector is offering a public funding opportunity titled "Factors Underlying Differences in Female and Male Presentation for Dental, Oral, and Craniofacial Diseases and Conditions (R21)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.121, 93.313, 93.866,.
- This funding opportunity was created on May 27, 2016 and posted on May 27, 2016.
- Applicants must submit their applications by Sep 07, 2019. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Each selected applicant is eligible to receive up to $200,000.00 in funding.
- Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For profit organizations other than small businesses, Small businesses, Others (see text field entitled Additional Information on Eligibility for clarification).
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
Factors Underlying Differences in Female and Male Presentation for Dental, Oral, and Craniofacial Diseases and Conditions (R21) (Funding Opportunity Number PA 16-296) is a discretionary NIH grant opportunity from HHS-NIH that supports exploratory and early-stage research focused on why dental, oral, and craniofacial (DOC) diseases can look, progress, or respond differently in females versus males. The core goal is to push forward mechanism-driven studies that can explain sex-based differences in disease manifestation, with an emphasis on generating new leads, testing novel ideas, and collecting preliminary data that could later support larger, more definitive projects. Because it uses the R21 mechanism, the intent is developmental and hypothesis-generating rather than requiring a fully mature research program at the outset.
The FOA specifically encourages investigators to examine biological and contextual factors that may drive these female-male differences. Priority scientific themes called out in the announcement include immune reactivity (for example, differences in inflammatory pathways, autoimmunity, or immune surveillance), genetic variation (including sex-linked effects, gene-by-sex interactions, and differential gene regulation), environmental triggers (such as exposures or behaviors that may interact with biology in sex-specific ways), aging (including how risk or symptom profiles change across the lifespan), and hormonal changes (including puberty, reproductive years, pregnancy-related influences, menopause/andropause-related shifts, and the effects of endogenous or exogenous hormones). In practice, the FOA is looking for projects that move beyond simply documenting disparities and instead dig into the mechanisms that could explain them.
The scope of supported conditions spans DOC-related diseases broadly, and the FOA highlights several examples to illustrate the kinds of topics it is aiming to stimulate. These include Sjogren syndrome, where autoimmune mechanisms and salivary gland dysfunction often show strong sex skew; orofacial pain conditions, where pain processing, neuroimmune interactions, and hormonal influences may differ by sex; temporomandibular joint disorder (TMD), including temporomandibular joint (TMJ) disorders, which are frequently reported at higher rates in women and may involve differences in musculoskeletal biology, pain sensitization, or stress-related pathways; salivary gland tumors, where sex differences could reflect hormonal receptor biology, immune microenvironments, or distinct molecular drivers; and HPV-associated oropharyngeal cancers, where sex-based differences may relate to immune response to HPV, behavioral exposures, viral persistence, or tumor biology. The language "including, but not limited to" signals that other DOC diseases and conditions are also eligible if the proposal is strongly aligned with the theme of sex-based mechanistic differences.
From an administrative standpoint, this is a grant (Funding Instrument Type: Grant) in the health research category, associated with CFDA numbers 93.121, 93.313, and 93.866. The award ceiling listed is $200,000, consistent with the smaller-scale, exploratory nature of R21 projects. The opportunity was posted on May 27, 2016, with an original and current closing date of September 7, 2019, indicating it was a time-bounded announcement in its posted form. The expected number of awards is not specified in the provided data, which typically means funding levels may depend on NIH priorities and available appropriations during the relevant cycle.
Eligibility is broad and includes a wide range of domestic applicant organizations: state, county, city/township, and special district governments; public and state-controlled institutions of higher education; private institutions of higher education; independent school districts; federally recognized Native American tribal governments and other tribal organizations; public housing authorities/Indian housing authorities; nonprofit organizations both with and without 501(c)(3) status (as long as they are not higher education institutions when applying under that category); for-profit organizations other than small businesses; and small businesses. The inclusion of many organizational types is meant to bring in diverse research settings, from academic labs and medical centers to nonprofit research institutes and qualified industry groups.
Overall, the FOA is best understood as a targeted call for innovative, mechanism-oriented pilot studies that can clarify why females and males experience certain oral and craniofacial diseases differently, with the longer-term public health aim of improving prevention, diagnosis, and treatment strategies that account for sex-based biology and related influences.
Frequently Asked Questions (FAQs)
What is the name of this grant opportunity?
The opportunity is titled "Factors Underlying Differences in Female and Male Presentation for Dental, Oral, and Craniofacial Diseases and Conditions (R21)."
What is the Funding Opportunity Number (FOA number)?
The Funding Opportunity Number is PA 16-296.
Which agency is offering this funding?
This is a discretionary NIH grant opportunity from HHS-NIH.
What type of funding instrument is this?
The funding instrument type is a Grant.
What research area does this FOA focus on?
It supports research in dental, oral, and craniofacial (DOC) diseases and conditions, specifically focused on understanding why these diseases can present, progress, or respond to treatment differently in females versus males.
What is the main goal of the FOA?
The core goal is to advance mechanism-driven studies that explain sex-based differences in DOC disease manifestation, with an emphasis on generating new leads, testing novel ideas, and collecting preliminary data that could support later, larger projects.
What does the R21 mechanism imply about the kind of projects NIH wants?
Because it uses the R21 mechanism, the intent is exploratory and early-stage research. Projects are expected to be developmental and hypothesis-generating rather than requiring a fully mature research program at the outset.
Does the FOA want projects that only document sex differences?
No. The FOA emphasizes moving beyond documenting disparities and instead focusing on mechanisms that could explain female-male differences in disease presentation, progression, or response.
What kinds of factors does the FOA encourage investigators to study?
The FOA specifically encourages examination of biological and contextual factors that may drive female-male differences, including immune reactivity, genetic variation, environmental triggers, aging, and hormonal changes.
What does "immune reactivity" mean in this FOA?
Examples provided include differences in inflammatory pathways, autoimmunity, or immune surveillance that could contribute to sex-based differences in DOC diseases and conditions.
What genetic topics are encouraged under this announcement?
The FOA highlights genetic variation topics such as sex-linked effects, gene-by-sex interactions, and differential gene regulation as potential contributors to differences between females and males.
Are environmental or behavioral factors within scope?
Yes. The FOA calls out environmental triggers, including exposures or behaviors that may interact with biology in sex-specific ways.
How does aging fit into the FOA's scientific priorities?
Aging is specifically included, with interest in how risk or symptom profiles change across the lifespan and how those changes may differ between females and males.
What kinds of hormonal influences are relevant to this FOA?
The FOA highlights hormonal changes across puberty, reproductive years, pregnancy-related influences, menopause/andropause-related shifts, and the effects of endogenous or exogenous hormones.
Which diseases and conditions are specifically mentioned as examples?
Examples mentioned include Sjogren syndrome, orofacial pain conditions, temporomandibular joint disorder (TMD) including temporomandibular joint (TMJ) disorders, salivary gland tumors, and HPV-associated oropharyngeal cancers.
Are applications limited only to the example conditions listed?
No. The FOA uses "including, but not limited to," indicating other dental, oral, and craniofacial diseases and conditions may be eligible if strongly aligned with the theme of mechanistic sex-based differences.
Why does the FOA mention Sjogren syndrome?
It is highlighted as an example where autoimmune mechanisms and salivary gland dysfunction often show strong sex skew, making it relevant to studies of female-male differences.
Why are orofacial pain conditions emphasized?
The FOA points to possible sex-related differences in pain processing, neuroimmune interactions, and hormonal influences as reasons these conditions are a good fit for mechanistic investigation.
Why does the FOA call out TMD/TMJ disorders?
TMD/TMJ disorders are frequently reported at higher rates in women, and the FOA notes possible mechanistic drivers such as musculoskeletal biology, pain sensitization, and stress-related pathways.
What kinds of sex-difference mechanisms might be studied in salivary gland tumors?
The FOA notes examples such as hormonal receptor biology, immune microenvironments, or distinct molecular drivers that could differ by sex.
What kinds of sex-difference mechanisms might be studied in HPV-associated oropharyngeal cancers?
The FOA mentions possibilities such as differences in immune response to HPV, behavioral exposures, viral persistence, or tumor biology.
What is the award ceiling for this opportunity?
The listed award ceiling is $200,000, consistent with the smaller-scale, exploratory nature of R21 projects.
Is the expected number of awards provided?
No. The expected number of awards is not specified in the provided information, which often means awards may depend on NIH priorities and available appropriations during the relevant cycle.
What are the CFDA numbers associated with this opportunity?
The opportunity is associated with CFDA numbers 93.121, 93.313, and 93.866.
When was this opportunity posted?
The opportunity was posted on May 27, 2016.
What is the closing date for the opportunity as provided?
The original and current closing date listed is September 7, 2019.
Is this a time-bounded opportunity based on the dates provided?
Yes. The information provided indicates it was time-bounded in its posted form, based on the listed closing date of September 7, 2019.
Who is eligible to apply?
Eligibility is broad and includes many domestic applicant organization types, including various levels of government, higher education institutions (public and private), tribal governments and tribal organizations, public housing authorities/Indian housing authorities, nonprofits (with and without 501(c)(3) status, under the stated category condition), for-profit organizations other than small businesses, and small businesses.
Are state and local government entities eligible?
Yes. Eligible applicants include state governments, county governments, city/township governments, and special district governments.
Are colleges and universities eligible?
Yes. Eligible applicants include public and state-controlled institutions of higher education and private institutions of higher education.
Are tribal entities eligible?
Yes. Federally recognized Native American tribal governments and other tribal organizations are listed as eligible.
Are nonprofit organizations eligible?
Yes. Nonprofit organizations with and without 501(c)(3) status are included, with the stated condition that they are not higher education institutions when applying under that category.
Are for-profit organizations eligible?
Yes. For-profit organizations other than small businesses are eligible, and small businesses are also explicitly listed as eligible.
What is the broader public health purpose of the research supported by this FOA?
The longer-term aim described is to improve prevention, diagnosis, and treatment strategies for dental, oral, and craniofacial diseases by accounting for sex-based biology and related influences.
Browse more opportunities from the same agency: HHS-NIH11
Browse more opportunities from the same category: Health
Next opportunity: Pilot Studies to Detect and Prevent Suicide Behavior, Ideation and Self-Harm in Youth in Contact with the Juvenile Justice System (R34)
Previous opportunity: Cooperative Ecosystem Studies Unit
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PA 16 296
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (PA 16 296) also looked into and applied for these:
| Funding Opportunity |
|---|
| Pilot Studies to Detect and Prevent Suicide Behavior, Ideation and Self-Harm in Youth in Contact with the Juvenile Justice System (R34) Apply for PAR 16 298 Funding Number: PAR 16 298 Agency: HHS-NIH11 Category: Health Funding Amount: $225,000 |
| Detecting and Preventing Suicide Behavior, Ideation and Self-Harm in Youth in Contact with the Juvenile Justice System (R01) Apply for PAR 16 299 Funding Number: PAR 16 299 Agency: HHS-NIH11 Category: Health Funding Amount: $500,000 |
| “Expanding Comprehensive HIV Prevention Programs for People Who Inject Drugs and People Who Use Drugs in the United Republic of Tanzania under the President’s Emergency Plan for AIDS Relief (PEPFAR)” TANZANIZ Apply for CDC RFA GH12 123804CONT16 Funding Number: CDC RFA GH12 123804CONT16 Agency: HHS-CDC-CGH Category: Health Funding Amount: Case Dependent |
| Strengthening and the Development of Applied Epidemiology and Sustainable Public Health Capacity through Collaboration, Program development and Implementation, Communication, and Information Sharing in the Eastern Mediterranean Region Apply for CDC RFA GH16 1704 Funding Number: CDC RFA GH16 1704 Agency: HHS-CDC-CGH Category: Health Funding Amount: $4,000,000 |
| Partnering with Regional Institutes to Strengthen Essential Public Health Functions in Vietnam Apply for CDC RFA GH16 1718 Funding Number: CDC RFA GH16 1718 Agency: HHS-CDC-CGH Category: Health Funding Amount: Case Dependent |
| Data Coordinating Center for Multi-Site Investigator-Initiated Clinical Trials (Collaborative U24) Apply for PAR 16 301 Funding Number: PAR 16 301 Agency: HHS-NIH11 Category: Health Funding Amount: Case Dependent |
| Clinical Coordinating Center for Multi-Site Investigator-Initiated Clinical Trials (Collaborative UG3/UH3) Apply for PAR 16 300 Funding Number: PAR 16 300 Agency: HHS-NIH11 Category: Health Funding Amount: Case Dependent |
| Programs to Reduce Obesity in High Obesity Areas to Boost Prevention Apply for CDC RFA DP16 1613 Funding Number: CDC RFA DP16 1613 Agency: HHS-CDC-NCCDPHP Category: Health Funding Amount: $800,000 |
| Continuation of Immunization Information Systems (IIS) Sentinel Site Project Apply for CDC RFA IP13 13020401SUPP16 Funding Number: CDC RFA IP13 13020401SUPP16 Agency: HHS-CDC-NCIRD Category: Health Funding Amount: Case Dependent |
| Resilient and Responsive Health Systems (RRHS) Initiative Apply for HRSA 17 007 Funding Number: HRSA 17 007 Agency: HHS-HRSA Category: Health Funding Amount: Case Dependent |
| Biosensors in the Oral Cavity (R21) Apply for RFA DE 17 005 Funding Number: RFA DE 17 005 Agency: HHS-NIH11 Category: Health Funding Amount: $200,000 |
| Biosensors in the Oral Cavity (R01) Apply for RFA DE 17 004 Funding Number: RFA DE 17 004 Agency: HHS-NIH11 Category: Health Funding Amount: $250,000 |
| NIDCD Mentored Career Development Award for Postdoctorate Au.D./Ph.D. Audiologists (K01) Apply for PAR 16 320 Funding Number: PAR 16 320 Agency: HHS-NIH11 Category: Health Funding Amount: Case Dependent |
| NIDCR Mentored Career Development Award to Promote Diversity in the Dental, Oral and Craniofacial Research Workforce (K01) Apply for PAR 16 321 Funding Number: PAR 16 321 Agency: HHS-NIH11 Category: Health Funding Amount: Case Dependent |
| Accelerating the Prevention and Control of HIV/AIDS, Viral Hepatitis, STDs and TB in the U.S. Affiliated Pacific Islands Apply for CDC RFA PS13 130105CONT17 Funding Number: CDC RFA PS13 130105CONT17 Agency: HHS-CDC-NCHHSTP Category: Health Funding Amount: Case Dependent |
| R40 MCH Secondary Data Analysis Research (SDAR) Apply for HRSA 17 012 Funding Number: HRSA 17 012 Agency: HHS-HRSA Category: Health Funding Amount: Case Dependent |
| R40 MCH Field-Initiated Innovative Research Studies (FIRST) Apply for HRSA 17 011 Funding Number: HRSA 17 011 Agency: HHS-HRSA Category: Health Funding Amount: Case Dependent |
| PPHF 2016: Preventive Health and Health Services Block Grant – Preventive Health and Health Services Block Grant Apply for CDC RFA OT16 1600PPHF16 Funding Number: CDC RFA OT16 1600PPHF16 Agency: HHS-CDC-OSTLTS Category: Health Funding Amount: Case Dependent |
| Emerging Science and Technology in Transplantation (U01) Apply for RFA AI 16 042 Funding Number: RFA AI 16 042 Agency: HHS-NIH11 Category: Health Funding Amount: $250,000 |
| Transforming Clinical Practice Initiative (TCPI) Support and Alignment Network (SAN) 2.0 Apply for CMS 1L1 16 001 Funding Number: CMS 1L1 16 001 Agency: HHS-CMS Category: Health Funding Amount: $2,500,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PA 16 296", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.